MA29989B1 - Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie - Google Patents

Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie

Info

Publication number
MA29989B1
MA29989B1 MA30264A MA30264A MA29989B1 MA 29989 B1 MA29989 B1 MA 29989B1 MA 30264 A MA30264 A MA 30264A MA 30264 A MA30264 A MA 30264A MA 29989 B1 MA29989 B1 MA 29989B1
Authority
MA
Morocco
Prior art keywords
treatment
pyridoazepine
tetrahydro
ones
schizophrenia
Prior art date
Application number
MA30264A
Other languages
English (en)
Inventor
David Alan Favor
Douglas Scott Johnson
Joseph Thomas Repine
Andrew David White
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA29989B1 publication Critical patent/MA29989B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Tétrahydro-pyridoazépine-8-ones et composés apparentés, pour le traitement de la schizophrénie II est décrit des composés de formule 1 dans laquelle G, D, A, Q, Y, Z et R1 à R10 sont définis dans le présent mémoire. Il est; proposé également des descriptions de procédés pour la préparation des composés de formule 1, les intermédiaires utilisés dans leur préparation, et des compositions pharmaceutiques contenant ces composés, et leur utilisation dans le traitement de troubles du système nerveux central et d'autres troubles.
MA30264A 2005-04-01 2007-10-01 Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie MA29989B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66744705P 2005-04-01 2005-04-01

Publications (1)

Publication Number Publication Date
MA29989B1 true MA29989B1 (fr) 2008-12-01

Family

ID=36763625

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30264A MA29989B1 (fr) 2005-04-01 2007-10-01 Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie

Country Status (25)

Country Link
US (1) US20060234997A1 (fr)
EP (1) EP1869041A1 (fr)
JP (1) JP4109709B1 (fr)
KR (1) KR20070112228A (fr)
CN (1) CN101189237A (fr)
AP (1) AP2007004160A0 (fr)
AR (1) AR053835A1 (fr)
AU (1) AU2006228426A1 (fr)
BR (1) BRPI0607918A2 (fr)
CA (1) CA2603049A1 (fr)
CR (1) CR9407A (fr)
DO (1) DOP2006000071A (fr)
EA (1) EA200701856A1 (fr)
GT (1) GT200600130A (fr)
IL (1) IL185770A0 (fr)
MA (1) MA29989B1 (fr)
MX (1) MX2007012083A (fr)
NL (2) NL1031489C2 (fr)
NO (1) NO20075477L (fr)
PE (1) PE20061196A1 (fr)
TN (1) TNSN07366A1 (fr)
TW (1) TW200714282A (fr)
UY (1) UY29447A1 (fr)
WO (1) WO2006103559A1 (fr)
ZA (1) ZA200708033B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116265A1 (fr) * 2006-03-31 2007-10-18 Pfizer Products Inc. Procede de fabrication d'un compose de tetrahydro-pyridoazepin-8-one
US8674790B2 (en) 2009-12-28 2014-03-18 Seiko Epson Corporation Surface acoustic wave device, oscillator, module apparatus
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6929857B2 (ja) 2016-01-15 2021-09-01 ファイザー・インク ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US20240217977A1 (en) * 2021-03-31 2024-07-04 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
EP4463229A1 (fr) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Formes cristallines de ((s)-5-benzyl-n-(5-méthyl-4-oxo-2, 3,4,5- tétrahydropyrido [3,2-b] [l,4]oxazépin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005828B1 (fr) * 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft Nouvelles dérivés de la phénylpipérazine substitués, médicaments les contenant et procédés pour leur préparation
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
FR2699918B1 (fr) * 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
DOP2006000071A (es) 2006-10-15
UY29447A1 (es) 2006-10-31
TNSN07366A1 (fr) 2008-12-31
AP2007004160A0 (en) 2007-10-31
ZA200708033B (en) 2008-11-26
AU2006228426A1 (en) 2006-10-05
CR9407A (es) 2008-01-29
NO20075477L (no) 2007-12-13
KR20070112228A (ko) 2007-11-22
US20060234997A1 (en) 2006-10-19
NL1033562C2 (nl) 2007-10-23
PE20061196A1 (es) 2006-12-16
GT200600130A (es) 2007-02-14
CN101189237A (zh) 2008-05-28
NL1031489C2 (nl) 2007-04-02
NL1033562A1 (nl) 2007-06-21
JP2008534574A (ja) 2008-08-28
JP4109709B1 (ja) 2008-07-02
EA200701856A1 (ru) 2008-02-28
NL1031489A1 (nl) 2006-10-03
TW200714282A (en) 2007-04-16
IL185770A0 (en) 2008-01-06
CA2603049A1 (fr) 2006-10-05
AR053835A1 (es) 2007-05-23
MX2007012083A (es) 2007-11-20
EP1869041A1 (fr) 2007-12-26
WO2006103559A1 (fr) 2006-10-05
BRPI0607918A2 (pt) 2009-10-20

Similar Documents

Publication Publication Date Title
TNSN07366A1 (fr) Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
TNSN05250A1 (fr) Pyrimidinones substituees
MA29429B1 (fr) Composes d'arylamine substitues et leur utilisation comme modulateurs de 5-ht6
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA26864A1 (fr) Antagonistes du facteur de liberation de corticotrophine.
TNSN07380A1 (fr) [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA28271A1 (fr) Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98237A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26722A1 (fr) Nouveaux composes et medicaments les contenant
MA26729A1 (fr) Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant